Pfizer lost more than $2 billion in the third quarter as an expected COVID-19 product sales decline clipped revenue.
Sales of the drugmaker’s COVID treatment Paxlovid and the vaccine Comirnaty slid 97% and 70%, respectively, as Pfizer, like its competitors, switched to selling on the commercial market instead of to governments.
Both the company and analysts who follow it expected revenue from those key products to tumble this year before eventually rebounding as commercial sales take hold. But two weeks ago, Pfizer Inc. warned that sales of its COVID-19 drugs were weaker than it had expected, and it cut its annual revenue expectations by $9 billion.
Falling sales of both Paxlovid and Comirnaty also trimmed sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023.
In the third quarter, the drugmaker booked a non-cash, $5.6 billion charge for inventory write-offs of the COVID products.
Outside those products, the drugmaker said its operational revenue grew 10%, helped in part by growth from its Prevnar pneumonia vaccines.
Pfizer also had a revenue reversal of more than $4 billion in the third quarter. That was tied to the return of nearly 8 million courses of Paxlovid from the U.S. government. Spokeswoman Pam Eisele said that was a credit that will be booked as revenue next year when the company delivers more treatment courses on the commercial market.
Overall, the New York company reported a loss adjusted for one-time gains or losses of 17 cents per share. That was much narrower loss than the 42 cents that Wall Street had expected, according to a survey of industry analysts by FactSet.
Total revenue fell 42% to $13.23 billion. Analysts had forecast revenue of $13.77 billion.
Pfizer expects full-year adjusted earnings of $1.45 to $1.65 per share.
Analysts expect, on average, earnings of $2.13 per share, according to FactSet.
Pfizer shares slid 2% to $29.93 after markets opened Tuesday, AP reports.
